Sign in

NCT04502758Completed

Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation

A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder

Source: ClinicalTrials.gov · Last updated 5 Aug 2026

Brief summary (registry, in English)

The purpose of this study is to gather information regarding the use of a new type of transcranial magnetic stimulation (TMS) called theta burst stimulation (TBS) for suicidal ideation in adolescents with Major Depressive Disorder (MDD). The investigators hope to learn if this TMS treatment improves suicidal ideation over 10 days and clinical outcomes over 1 year of follow-up.

Status (registry)
Completed
Study type
Interventional
Enrollment
58 (actual)
First submitted
4 Aug 2020
Start date
4 Apr 2022
Primary completion date
30 Jun 2026
Lead sponsor
Mayo Clinic
Diseases
Depression
NCT number
NCT04502758

What you commit to

  • Study type: Interventional
  • Participants enrolled: 58
  • From 4 Apr 2022 to the primary completion date, 30 Jun 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Positive urine drug screen at baseline
  • History of any treatment with electroconvulsive therapy or TMS
  • Use of any investigational drug within 4 weeks of baseline
  • Prior brain surgery
  • Conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the head-within 30 cm of the treatment coil excluding the mouth that cannot be safely removed (examples include cochlear implants, vagus nerve stimulators, deep brain stimulators, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes).

Other illness

  • Diagnosis of a psychotic disorder, bipolar disorder, anorexia nervosa, bulimia nervosa, substance use disorders within the past year (with the exception of caffeine and tobacco).
  • Seizure history
  • Any family history of epilepsy
  • Implanted medication pumps and cardiac pacemakers
  • Any unstable medical condition

Other

  • Intelligent quotient less than 70 (if there is a clinical concern, subjects will be psychometrically assessed with the Slosson Intelligence Test, Revised).123
  • Risk for increased intracranial pressure such as a brain tumor
  • Head trauma with loss of consciousness
  • Any true positive findings on the TMS safety screening form
  • Pregnancy or suspected pregnancy
  • Inability to adhere to the protocol

Who the study is looking for

  • Inpatients or outpatients
  • Voluntary clinical patient with the capacity to assent to treatment and a parent or legal guardian with the capacity to consent
  • Female or male
  • 12-18 years of age
  • Diagnosed with MDD based on Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) criteria122 with the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI Kid) in subjects 12-17 years of age;118 The Mini-International Neuropsychiatric Interview will be used for subjects who are 18 years of age117
  • In a current episode of MDD with duration of at least 4 weeks but less than 3 years
  • Depressive symptom severity as demonstrated by CDRS-R total composite score of 40 or greater and a suicidal ideation score of 3 or more on item 13 of the CDRS-R109
  • Demonstrating that depressive symptom severity as evaluated at the screening visit does not improve between screening and baseline by 25% or more
  • Eligible for transcranial magnetic stimulation (TMS) based on safety criteria104
  • On a medically acceptable form of birth control if female
  • Taking an antidepressant medication if recommended by the referring clinician and agreed upon by parents and patients. Please note that patients are not required to take an antidepressant medication for study participation for practical, ethical, and human subject protection concerns. Medication status and prior treatment resistance will be carefully recorded with the Antidepressant Treatment History Form113 criteria for relevant statistical considerations.

Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Mayo Clinic in Rochester
Coordinator of this site? Confirm its status
RochesterUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.